Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer
ConclusionWe did not detect significant changes in AHT use after the HDHP switch. Findings might be related to modest increases in overall AHT OOP costs, the availability of low-cost generic tamoxifen, and patient awareness that AHT can prolong life and health. Minimizing OOP cost increases for essential medications might represent a feasible approach for maintaining medication adherence among HDHP members with incident breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Health Insurance | Hormonal Therapy | Hormones | Insurance | Insurers | Study | Tamoxifen | Women